FORUM MARKETS Inc
FRMMNasdaq
$5.68
↓ -2.8%Jul 17 close · end-of-day
Price
1Y↓ -35.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$121.0M
Enterprise Value
$23.3M
P/E
—
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$524.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-311.5%
ROIC
-264.0%
Debt / Equity
—
Net Cash
$97.7M
Return 1Y
-69.0%
Company profile
1180 Life Sciences Corp. develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
- CEO
- Jim N. Woody
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 7
- Headquarters
- California
- Website
- 180lifesciences.com
Management & directors
- Rudisill McandrewChief Executive Officer
- Saunders John TazewellChief Financial Officer
- Jordan BlairChief Executive Officer
- Van Lent Eric RChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
FRMM Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.9M—
Diluted EPS-$3.64↓ -34.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $6.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$5.6M | -$15.6M | -$17.9M | -$13.5M | -$4.4M | -$233.4M |
| Net income | -$10.9M | -$20.3M | -$38.7M | -$19.9M | -$6.2M | -$450.5M |
| Diluted EPS | — | -$12.96 | -$387.18 | -$52.59 | -$28.56 | -$54.32 |
| Operating cash flow | -$3.9M | -$19.4M | -$12.1M | -$10.9M | -$1.2M | -$26.1M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -3565.8% |
| Net margin | — | — | — | — | — | -6881.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $4.1M | — | $2.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$1.8M | -$596,172.00 | $116,378.00 | -$2.0M | -$1.7M | -$220.5M | -$9.3M | -$4.6M |
| Net income | $11,781.00 | -$836,720.00 | -$4.3M | -$2.4M | -$1.7M | -$216.7M | -$229.7M | -$76.3M |
| Diluted EPS | $0.01 | -$5.43 | -$21.46 | -$5.54 | -$0.30 | -$16.80 | -$31.68 | -$3.64 |
| Operating cash flow | $727,170.00 | -$239,930.00 | -$624,823.00 | -$887,000.00 | -$1.1M | -$16.4M | -$7.6M | -$20.4M |
| Free cash flow | — | — | — | — | — | — | — | -$37.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -5364.6% | — | -162.0% |
| Net margin | — | — | — | — | — | -5273.3% | — | -2667.5% |
Company news
Sep 12, 2025
Sep 8, 2025
Aug 25, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-15 | Lomashuk Konstantin | Sale | 2,562 | $6.30 | $16,140.86 | filing |
| 2026-07-09 | Lomashuk Konstantin | Sale | 3,387 | $6.15 | $20,846.31 | filing |
| 2026-07-08 | Lomashuk Konstantin | Sale | 1,100 | $6.13 | $6,743.00 | filing |
| 2026-07-07 | Lomashuk Konstantin | Sale | 3,702 | $6.41 | $23,733.89 | filing |
| 2026-04-02 | Dalton Angela | Award | 203,562 | $0.00 | $0.00 | filing |
| 2026-04-02 | Edwards Michael A | Award | 203,562 | $0.00 | $0.00 | filing |
| 2026-04-02 | SUCKLING ANDREW P | Award | 241,918 | $0.00 | $0.00 | filing |
| 2026-04-02 | Smith Ryan Lewis | Award | 241,918 | $0.00 | $0.00 | filing |
| 2026-04-02 | Saunders John Tazewell· Chief Financial Officer | Award | 358,592 | $0.00 | $0.00 | filing |
| 2026-04-02 | Rudisill McAndrew· Chief Executive Officer | Award | 1,884,979 | $0.00 | $0.00 | filing |
| 2026-04-02 | New Jason Griffin | Award | 241,918 | $0.00 | $0.00 | filing |
| 2026-04-02 | Heter Crystal Jane | Award | 241,918 | $0.00 | $0.00 | filing |
| 2026-02-18 | Smith Ryan Lewis | J | 16,718 | $0.00 | $0.00 | filing |
| 2025-12-01 | Smith Ryan Lewis | Gift | 16,718 | $0.00 | $0.00 | filing |
| 2025-12-01 | Smith Ryan Lewis | Gift | 16,718 | $0.00 | $0.00 | filing |
| 2025-11-14 | Rudisill McAndrew· Chief Executive Officer | Gift | 410,865 | $0.00 | $0.00 | filing |
| 2025-11-14 | Rudisill McAndrew· Chief Executive Officer | Gift | 370,000 | $0.00 | $0.00 | filing |
| 2025-11-14 | Heter Crystal Jane | Gift | 182,742 | $0.00 | $0.00 | filing |
| 2025-11-14 | Heter Crystal Jane | Gift | 182,742 | $0.00 | $0.00 | filing |
| 2025-11-14 | SUCKLING ANDREW P | Gift | 149,020 | $0.00 | $0.00 | filing |
| 2025-11-14 | SUCKLING ANDREW P | Gift | 149,020 | $0.00 | $0.00 | filing |
| 2025-11-14 | Smith Ryan Lewis | Gift | 267,137 | $0.00 | $0.00 | filing |
| 2025-11-14 | Smith Ryan Lewis | Gift | 267,137 | $0.00 | $0.00 | filing |
| 2025-11-14 | New Jason Griffin | Gift | 218,456 | $0.00 | $0.00 | filing |
| 2025-11-14 | New Jason Griffin | Gift | 218,456 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.